LMR Partners’s Psyence Biomedical Warrant PBMWW Stock Holding History

LMR Partners’s Portfolio PBMWW Stock Details PBMWW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.86K	Hold	200,000	–	–	﹤0.01%	1461
2026 Q1	$3.64K	Hold	200,000	–	–	﹤0.01%	1393
2025 Q4	$3.7K	Hold	200,000	–	–	﹤0.01%	1464
2025 Q3	$5.04K	Hold	200,000	–	–	﹤0.01%	1398
2025 Q2	$4.06K	Hold	200,000	–	–	﹤0.01%	1310
2025 Q1	$3.38K	Hold	200,000	–	–	﹤0.01%	1297
2024 Q4	$2.88K	Buy	+200,000	New	+$2.66K	﹤0.01%	1146
2024 Q3	–	Sell	-200,000	Closed	-$3.5K	–	1551
2024 Q2	$2.1K	Hold	200,000	–	–	﹤0.01%	1063
2024 Q1	$14K	Buy	+200,000	New	+$12.5K	﹤0.01%	1045

Other funds holding PBMWW

HCI

Harraden Circle Investments New York $784M AUM 20.59% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

TCM

Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return

LMR Partners's PBMWW Position: Q2 2026 in Review

LMR Partners held its Psyence Biomedical Warrant (PBMWW) position steady in Q2 2026 at 200,000 shares worth $4.86K. The position accounts for ﹤0.01% of the portfolio, ranked #1461.

LMR Partners first reported a position in PBMWW in Q1 2024 and has held it in 9 quarters since. The position peaked at $14K in Q1 2024. 18 funds tracked by Wall St. Rank hold PBMWW as of Q2 2026.

LMR Partners held 200,000 shares of Psyence Biomedical Warrant worth $4.86K as of Q2 2026.
LMR Partners left its Psyence Biomedical Warrant share count unchanged in Q2 2026.
Psyence Biomedical Warrant made up ﹤0.01% of LMR Partners's portfolio in Q2 2026, its #1461 holding.
LMR Partners first reported a position in Psyence Biomedical Warrant in Q1 2024 and has held it in 9 quarters since.
LMR Partners's Psyence Biomedical Warrant position peaked at $14K in Q1 2024.
18 funds tracked by Wall St. Rank held Psyence Biomedical Warrant as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.